Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure.

Tahir UA, Doros G, Kim JS, Connors LH, Seldin DC, Sam F.

Sci Rep. 2019 Jun 12;9(1):8552. doi: 10.1038/s41598-019-44912-x.

2.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.

Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.

PMID:
28550039
3.

Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.

Salinaro F, Meier-Ewert HK, Miller EJ, Pandey S, Sanchorawala V, Berk JL, Seldin DC, Ruberg FL.

Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1057-1064. doi: 10.1093/ehjci/jew298.

PMID:
27965280
4.

CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.

Lian H, Li D, Zhou Y, Landesman-Bollag E, Zhang G, Anderson NM, Tang KC, Roderick JE, Kelliher MA, Seldin DC, Fu H, Feng H.

Haematologica. 2017 Jan;102(1):e17-e21. doi: 10.3324/haematol.2016.154013. Epub 2016 Oct 6. No abstract available.

5.

Depression and anxiety in patients with AL amyloidosis as assessed by the SF-36 questionnaire: experience in 1226 patients.

Shu J, Lo S, Phillips M, Sun F, Seldin DC, Berenbaum I, Berk JL, Sanchorawala V.

Amyloid. 2016 Sep;23(3):188-193. Epub 2016 Jul 27.

PMID:
27460276
6.

Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.

Prokaeva T, Spencer B, Sun F, O'Hara RM, Seldin DC, Connors LH, Sanchorawala V.

Amyloid. 2016 Dec;23(4):214-220. Epub 2016 Sep 28.

PMID:
27677679
7.

Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.

Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC.

Blood. 2016 Aug 25;128(8):1059-62. doi: 10.1182/blood-2016-04-710822. Epub 2016 Jul 5.

PMID:
27381904
8.

Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.

Lee SY, Meehan RS, Seldin DC, Sloan JM, Quillen K, Shelton A, Brauneis D, Sanchorawala V.

Bone Marrow Transplant. 2016 Oct;51(10):1318-1322. doi: 10.1038/bmt.2016.132. Epub 2016 May 16.

PMID:
27183092
9.

The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells.

Stanford EA, Wang Z, Novikov O, Mulas F, Landesman-Bollag E, Monti S, Smith BW, Seldin DC, Murphy GJ, Sherr DH.

BMC Biol. 2016 Mar 16;14:20. doi: 10.1186/s12915-016-0240-y.

10.

Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.

Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC.

Circulation. 2016 Jan 19;133(3):282-90. doi: 10.1161/CIRCULATIONAHA.115.018852. Epub 2015 Dec 11.

11.

Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis.

Bever KM, Masha LI, Sun F, Stern L, Havasi A, Berk JL, Sanchorawala V, Seldin DC, Sloan JM.

Haematologica. 2016 Jan;101(1):86-90. doi: 10.3324/haematol.2015.133900. Epub 2015 Oct 9.

12.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience.

Sanchorawala V, Sun F, Quillen K, Sloan JM, Berk JL, Seldin DC.

Blood. 2015 Nov 12;126(20):2345-7. doi: 10.1182/blood-2015-08-662726. Epub 2015 Oct 6. No abstract available.

PMID:
26443620
13.

Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature.

Sarosiek S, Seldin DC, Connors LH, Spencer B, Murakami A, O'Hara C, Sanchorawala V.

Amyloid. 2015;22(3):156-62. doi: 10.3109/13506129.2015.1036983. Epub 2015 Jun 25.

PMID:
26104853
14.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2015 May;7(5):688. doi: 10.15252/emmm.201505318. No abstract available.

15.

Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.

Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1445-51. doi: 10.1016/j.bbmt.2015.04.001. Epub 2015 Apr 6.

16.

Serum free light chain trends between orthotopic heart transplantation and auto-SCT in patients with AL amyloidosis.

Renteria AS, Sanchorawala V, Niehaus ED, Sun F, Semigran MJ, Seldin DC.

Bone Marrow Transplant. 2015 Jun;50(6):868-9. doi: 10.1038/bmt.2015.9. Epub 2015 Mar 9. No abstract available.

PMID:
25751645
17.

Cooperative stabilization of transthyretin by clusterin and diflunisal.

Greene MJ, Klimtchuk ES, Seldin DC, Berk JL, Connors LH.

Biochemistry. 2015 Jan 20;54(2):268-78. doi: 10.1021/bi5011249. Epub 2014 Dec 24.

18.

Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt).

Sikora JL, Logue MW, Chan GG, Spencer BH, Prokaeva TB, Baldwin CT, Seldin DC, Connors LH.

Hum Genet. 2015 Jan;134(1):111-21. doi: 10.1007/s00439-014-1499-0. Epub 2014 Nov 4.

19.

Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity.

Guan J, Mishra S, Qiu Y, Shi J, Trudeau K, Las G, Liesa M, Shirihai OS, Connors LH, Seldin DC, Falk RH, MacRae CA, Liao R.

EMBO Mol Med. 2014 Nov;6(11):1493-507. doi: 10.15252/emmm.201404190. Erratum in: EMBO Mol Med. 2015 May;7(5):688.

20.

Lymphadenopathy as a manifestation of amyloidosis: a case series.

Fu J, Seldin DC, Berk JL, Sun F, O'Hara C, Cui H, Sanchorawala V.

Amyloid. 2014 Dec;21(4):256-60. doi: 10.3109/13506129.2014.958610. Epub 2014 Sep 10.

PMID:
25208081
21.

Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.

Freeman B, Brauneis D, Seldin DC, Quillen K, Sloan JM, Renteria AS, Shelton AC, Teschner T, Finn KT, Sanchorawala V.

Bone Marrow Transplant. 2014 Oct;49(10):1345-6. doi: 10.1038/bmt.2014.132. Epub 2014 Jun 23. No abstract available.

PMID:
24955784
22.

Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.

Lee SY, Sanchorawala V, Seldin DC, Mark Sloan J, Andrea N, Quillen K.

Amyloid. 2014 Sep;21(3):149-53. doi: 10.3109/13506129.2014.900486. Epub 2014 Apr 29.

PMID:
24779777
23.

Single agent lenalidomide three times a week induces hematologic responses in AL amyloidosis patients on dialysis.

Lichtman EI, Seldin DC, Shelton A, Sanchorawala V.

Am J Hematol. 2014 Jul;89(7):706-8. doi: 10.1002/ajh.23722. Epub 2014 Apr 10.

24.

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium.

JAMA. 2013 Dec 25;310(24):2658-67. doi: 10.1001/jama.2013.283815.

25.

Immunoglobulin light chain amyloidosis.

Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA.

Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. Review.

PMID:
24350907
26.

Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.

Girnius S, Seldin DC, Meier-Ewert HK, Sloan JM, Quillen K, Ruberg FL, Berk JL, Doros G, Sanchorawala V.

Bone Marrow Transplant. 2014 Mar;49(3):434-9. doi: 10.1038/bmt.2013.192. Epub 2013 Dec 9.

PMID:
24317129
27.

Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.

Leung A, Nah SK, Reid W, Ebata A, Koch CM, Monti S, Genereux JC, Wiseman RL, Wolozin B, Connors LH, Berk JL, Seldin DC, Mostoslavsky G, Kotton DN, Murphy GJ.

Stem Cell Reports. 2013 Oct 31;1(5):451-63. doi: 10.1016/j.stemcr.2013.10.003. eCollection 2013.

28.

Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.

Gray Gilstrap L, Niehaus E, Malhotra R, Ton VK, Watts J, Seldin DC, Madsen JC, Semigran MJ.

J Heart Lung Transplant. 2014 Feb;33(2):149-56. doi: 10.1016/j.healun.2013.09.004. Epub 2013 Nov 5.

29.

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity.

Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, Lavatelli F, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW Jr, Macrae CA, Liao R.

Basic Res Cardiol. 2013 Sep;108(5):378. doi: 10.1007/s00395-013-0378-5. Epub 2013 Aug 28.

30.

Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.

Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.

Bone Marrow Transplant. 2013 Nov;48(12):1537-42. doi: 10.1038/bmt.2013.98. Epub 2013 Jul 15.

31.

New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation.

Girnius S, Seldin DC, Cibeira MT, Sanchorawala V.

J Clin Oncol. 2013 Jul 20;31(21):2749-50. doi: 10.1200/JCO.2013.48.7736. Epub 2013 Jun 17. No abstract available.

PMID:
23775968
32.

Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.

Sanchorawala V, Shelton AC, Zeldis JB, Seldin DC.

Am J Hematol. 2013 Aug;88(8):719. doi: 10.1002/ajh.23470. Epub 2013 May 30. No abstract available.

33.

Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Mishra S, Guan J, Plovie E, Seldin DC, Connors LH, Merlini G, Falk RH, MacRae CA, Liao R.

Am J Physiol Heart Circ Physiol. 2013 Jul 1;305(1):H95-103. doi: 10.1152/ajpheart.00186.2013. Epub 2013 Apr 26.

34.

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.

Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC, Sam F.

J Am Heart Assoc. 2013 Mar 12;2(2):e005868. doi: 10.1161/JAHA.112.005868.

35.

A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature.

Sarosiek S, Seldin DC, Berk JL, Sanchorawala V.

Amyloid. 2013 Jun;20(2):127-30. doi: 10.3109/13506129.2013.775644. Epub 2013 Mar 6. Review.

PMID:
23461593
36.

Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.

Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V.

Transpl Infect Dis. 2013 Apr;15(2):187-94. doi: 10.1111/tid.12037. Epub 2012 Dec 20.

PMID:
23279695
37.

High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center.

Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, Doros G, Finn KT, Skinner M, Sanchorawala V.

Blood. 2012 Nov 22;120(22):4445-6. doi: 10.1182/blood-2012-09-457341. No abstract available.

PMID:
23175664
38.

Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial.

Sanchorawala V, Patel JM, Sloan JM, Shelton AC, Zeldis JB, Seldin DC.

Haematologica. 2013 May;98(5):789-92. doi: 10.3324/haematol.2012.075192. Epub 2012 Nov 9.

39.

Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report.

Shin JT, Ward JE, Collins PA, Dai M, Semigran HL, Semigran MJ, Seldin DC.

Amyloid. 2012 Dec;19(4):191-6. doi: 10.3109/13506129.2012.733741.

PMID:
23126591
40.

Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5.

Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE.

Cancer Res. 2012 Dec 1;72(23):6268-78. doi: 10.1158/0008-5472.CAN-12-2270. Epub 2012 Oct 10.

41.

A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms.

Girnius S, Skinner M, Spencer B, Prokaeva T, Bartholomew C, O'Hara C, Seldin DC, Connors LH.

Amyloid. 2012 Dec;19(4):182-5. doi: 10.3109/13506129.2012.723074. Epub 2012 Sep 14.

PMID:
22978355
42.

Expression of D-type cyclins in AL amyloidosis plasma cells.

Lee JC, Wu H, Prokaeva TB, O'Hara C, Seldin DC.

J Clin Pathol. 2012 Nov;65(11):1052-5. doi: 10.1136/jclinpath-2012-200819. Epub 2012 Aug 1. No abstract available.

PMID:
22859391
43.

Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment.

Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O'Hara C, Finn KT, Sanchorawala V.

Biol Blood Marrow Transplant. 2012 Dec;18(12):1935-8. doi: 10.1016/j.bbmt.2012.07.016. Epub 2012 Jul 27.

44.

Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.

Cowan AJ, Skinner M, Seldin DC, Berk JL, Lichtenstein DR, O'Hara CJ, Doros G, Sanchorawala V.

Haematologica. 2013 Jan;98(1):141-6. doi: 10.3324/haematol.2012.068155. Epub 2012 Jun 24.

45.

Foxk1 recruits the Sds3 complex and represses gene expression in myogenic progenitors.

Shi X, Seldin DC, Garry DJ.

Biochem J. 2012 Sep 15;446(3):349-57. doi: 10.1042/BJ20120563.

46.

Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: a case report and literature review.

Freeman B, Sloan JM, Seldin DC, Cowan AJ, Ruberg FL, Sanchorawala V.

Amyloid. 2012 Sep;19(3):156-60. doi: 10.3109/13506129.2012.694825. Epub 2012 Jun 11. Review.

PMID:
22680044
47.

Asymmetric Localization of CK2α During Xenopus Oogenesis.

Imbrie GA, Wu H, Seldin DC, Dominguez I.

Hum Genet Embryol. 2012 May 5;Suppl 4(1):11328.

48.

AL amyloidosis: who, what, when, why, and where.

Sanchorawala V, Seldin DC.

Oncology (Williston Park). 2012 Feb;26(2):164, 166, 169. No abstract available.

49.

Amyloidomics comes of age.

Seldin DC, Sanchorawala V.

Blood. 2012 Feb 23;119(8):1795-6. doi: 10.1182/blood-2011-10-381178.

PMID:
22361969
50.

Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Ward JE, Ren R, Toraldo G, Soohoo P, Guan J, O'Hara C, Jasuja R, Trinkaus-Randall V, Liao R, Connors LH, Seldin DC.

Blood. 2011 Dec 15;118(25):6610-7. doi: 10.1182/blood-2011-04-351643. Epub 2011 Oct 12.

Supplemental Content

Loading ...
Support Center